Advanced Heart Failure in the Cancer Patient
Introduction
Innovations in anti-neoplastic treatments have amplified the number of long-term survivors. Even with novel malignancy therapies, anthracyclines are the foundation of cancer treatment, especially in hematologic malignancies, sarcomas, and breast cancer.
Heart failure (HF) has been described in up to 10% of tumor survivors, and the progression to end-stage HF in 2% to 3%. According to estimations grounded on retrospective registry data, such as United Network for Organ Sharing (UNOS) or Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registries, 0.5-2.5% of patients undergoing advanced HF therapies such as left ventricular assist devices (LVAD) and orthotopic heart transplantation have had previous cancer treatment.
[…]
Comments are moderated by the editorial team before publication. Discussions should be evidence-based and use scientific language. Conflicts of interest should be declared.